Primary study · included by 1 review

A polycaprolactone/cuttlefish bone‐derived hydroxyapatite composite porous scaffold for bone tissue engineering

B. S. Kim 2014 · Kim Beom‐Su, Yang Sun‐Sik, Lee Jun · Journal of Biomedical Materials Research Part B: Applied Biomaterials · 2013

Included by

Polycaprolactone Scaffolds for BONE Regeneration in Animal Models of Cranial Defects: A Systematic Review and Meta-Analysis
Non-Cochrane · intervention · 2026 · cited as B. S. Kim 2014 · Figures 2-4; Table 4; reference [14]
Outcome this study informsPooled effectEvidenceCertainty
Bone regeneration (BV/TV, %) at 1-2 months (middle stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle)
QM = 0.019, df = 1, p = 0.891, R2 = 0%27 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
QM = 9.509, df = 3, p = 0.023, R2 = 28.8%20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
Meta-regression beta (difference in MD, %) 0.853 [-4.49, 6.195]20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
MD 1.68 [0.34, 3.03]18 studies · 194 participantsGRADE not reported
Bone regeneration (BV/TV, %) at 1-2 months (middle stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle)
QM = 0.148, df = 1, p = 0.701, R2 = 0%27 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
Meta-regression beta (difference in MD, %) -4.258 [-8.216, -0.3]20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at 1-2 months (middle stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle)
QM = 3.742, df = 2, p = 0.154, R2 = 6.4%27 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
QM = 0.703, df = 1, p = 0.402, R2 = 0%20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at 1-2 months (middle stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle)
MD 5.6 [3.48, 7.72]25 studies · 260 participantsGRADE not reported
Bone regeneration (BV/TV, %) at 1-2 months (middle stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle)
Meta-regression beta (difference in MD, %) 10.748 [-0.505, 22.001]27 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
Meta-regression beta (difference in MD, %) -6.987 [-12.867, -1.108]20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at 1-2 months (middle stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle)
Meta-regression beta (difference in MD, %) 1.677 [-3.37, 6.723]27 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
QM = 0.334, df = 1, p = 0.563, R2 = 0%20 studiesGRADE not reported

1 including review in total.